C4 Therapeutics, Inc. financial data

Symbol
CCCC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 120, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 563 % -14%
Debt-to-equity 54.1 % +1.58%
Return On Equity -42.5 % +21.2%
Return On Assets -27.6 % +21.7%
Operating Margin -354 % +48.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.6M shares +43.2%
Common Stock, Shares, Outstanding 70.6M shares +43.2%
Entity Public Float 130M USD -35.6%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 69.6M shares +41.5%
Weighted Average Number of Shares Outstanding, Diluted 69.6M shares +41.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 33.7M USD +65.5%
Research and Development Expense 109M USD -8.01%
General and Administrative Expense 42M USD -0.55%
Operating Income (Loss) -119M USD +14.7%
Nonoperating Income (Expense) 14.1M USD +136%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -105M USD +5.26%
Income Tax Expense (Benefit) 277K USD -100%
Net Income (Loss) Attributable to Parent -105M USD +21.8%
Earnings Per Share, Basic -1.7 USD/shares +38.2%
Earnings Per Share, Diluted -1.7 USD/shares +38.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.6M USD -2.17%
Marketable Securities, Current 264M USD +10.4%
Cash, Cash Equivalents, and Short-term Investments 284M USD +15.4%
Accounts Receivable, after Allowance for Credit Loss, Current 10.3M USD +1968%
Assets, Current 273M USD +22.1%
Property, Plant and Equipment, Net 6.21M USD -14.9%
Operating Lease, Right-of-Use Asset 59.2M USD -9.7%
Other Assets, Noncurrent 5.26M USD +64%
Assets 376M USD +12.9%
Accounts Payable, Current 1.5M USD +17.9%
Contract with Customer, Liability, Current 20.8M USD +147%
Liabilities, Current 43.3M USD +43%
Contract with Customer, Liability, Noncurrent 28.6M USD +46%
Operating Lease, Liability, Noncurrent 61.5M USD -8.39%
Liabilities 133M USD +14%
Accumulated Other Comprehensive Income (Loss), Net of Tax 455K USD
Retained Earnings (Accumulated Deficit) -599M USD -21.4%
Stockholders' Equity Attributable to Parent 243M USD +12.3%
Liabilities and Equity 376M USD +12.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.1M USD +45.3%
Net Cash Provided by (Used in) Financing Activities 34.6M USD
Net Cash Provided by (Used in) Investing Activities -53.4M USD -200%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 70.6M shares +43.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -36.9M USD -287%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63.1M USD -2.07%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 146M USD +32.2%
Deferred Tax Assets, Gross 166M USD +25.9%
Operating Lease, Liability 71M USD -6.2%
Depreciation 1.24M USD -37.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -104M USD +20.2%
Lessee, Operating Lease, Liability, to be Paid 89M USD -8.78%
Property, Plant and Equipment, Gross 15.1M USD -0.74%
Operating Lease, Liability, Current 5.63M USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.09M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.83M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.1M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.37M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 61M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.65M USD +2.99%
Operating Lease, Payments 2.18M USD +3.02%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 27.8M USD -0.03%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%